R. Coleman

发表

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

R. Laing, P. Ellis, H. Earl, 2017, The Lancet. Oncology.

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.

M. Gore, J. Carmichael, N. Davidson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

G. Jayson, P. Vasey, F. Blackhall, 2003, British Journal of Cancer.

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

J. Graham, S. M. Crawford, P. Vasey, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome

M. Seckl, R. Coleman, A. Sita-Lumsden, 2013, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

W. Gradishar, G. Dranitsaris, R. Coleman, 2010, Breast Cancer Research and Treatment.

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

G. Rustin, W. Oster, J. Ledermann, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

T. Delozier, E. Kreuser, D. Serin, 2005, British Journal of Cancer.

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

B. Monk, R. Burger, E. Swisher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study

M. Seckl, V. Harding, R. Harvey, 2020, BJOG : an international journal of obstetrics and gynaecology.

Endometrial carcinosarcoma

B. Monk, A. Mariani, S. Pignata, 2022, International Journal of Gynecological Cancer.

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer

G. Rustin, P. Vasey, S. Kaye, 2006, British Journal of Cancer.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Alan Gordon, James Paul, Gordon C Jayson, 2004, Journal of the National Cancer Institute.

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

A Gordon, M. Gore, J. Carmichael, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)

S. Pignata, U. Matulonis, Jiuzhou Wang, 2022, Gynecologic Oncology.

Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis (LBA 10)

V. Gebski, P. Ramirez, A. Obermair, 2022, Gynecologic Oncology.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

I. Ellis, M. Dowsett, P. Ellis, 2009, The Lancet.

Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

B. Monk, P. Thaker, K. Fuh, 2021, Gynecologic Oncology.

ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma

A. Jazaeri, Ying Yuan, K. Lu, 2021, Gynecologic Oncology.

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.

C. Denkert, A. Makris, J. Bartlett, 2021, JAMA oncology.

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.

D. Kerr, T. Powles, G. Rustin, 1992, Oncology.

P. Vasey, S. Kaye, J. Graham, 2022 .

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

I. Ellis, M. Dowsett, P. Ellis, 2009 .

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).

C. Poole, S. Kaye, J. Graham, 2006, European journal of cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer

Benoît Cadieux, A. Chan, R. Coleman, 2021, Advances in Therapy.